Pembrolizumab or Bevacizumab Plus Chemotherapy as First-Line Treatment of Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Retrospective Cohort Study

Pembrolizumab or Bevacizumab Plus Chemotherapy as First-Line Treatment of Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Retrospective Cohort Study

Objective: Pembrolizumab and bevacizumab both have antitumor activity. According to NCCN updated guideline the benefit of pembrolizumab or bevacizumab as a first line in management of advanced nonsmall cell lung cancer (NSCLC) is documented in randomized controlled studies. The study aimed to evalua...

Full description

Bibliographic Details
Main Authors: Jie Zhang PhD, Di Wu PhD, Ziran Zhang PhD, Jieran Long PhD, Guangming Tian PhD, Yang Wang PhD, Xiangjuan Ma PhD, Xiaoling Chen PhD, Jindi Han PhD, Weiheng Hu PhD, Ling Dai PhD, Jun Nie PhD, Jian Fang PhD
Format: Article
Language:English
Published: SAGE Publishing 2021-11-01
Series:Technology in Cancer Research & Treatment
Online Access:https://doi.org/10.1177/15330338211039676

Internet

https://doi.org/10.1177/15330338211039676

Similar Items